Masimo (NASDAQ:MASI) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

A number of other analysts have also weighed in on the stock. Needham & Company LLC initiated coverage on shares of Masimo in a report on Friday, September 14th. They set a “buy” rating on the stock. Stifel Nicolaus upped their target price on shares of Masimo from $112.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, October 2nd. Zacks Investment Research lowered shares of Masimo from a “buy” rating to a “hold” rating in a report on Wednesday, August 1st. Finally, Piper Jaffray Companies upped their target price on shares of Masimo to $120.00 and gave the stock a “neutral” rating in a report on Thursday, November 1st. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $114.40.

Masimo stock traded down $0.56 during midday trading on Tuesday, reaching $110.59. 421,914 shares of the stock were exchanged, compared to its average volume of 525,124. The firm has a market capitalization of $6.12 billion, a PE ratio of 45.14, a price-to-earnings-growth ratio of 2.72 and a beta of 1.11. Masimo has a 52 week low of $80.69 and a 52 week high of $126.89.

Masimo (NASDAQ:MASI) last posted its earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.69 by $0.02. The business had revenue of $210.58 million for the quarter, compared to analyst estimates of $207.62 million. Masimo had a net margin of 17.08% and a return on equity of 20.29%. Masimo’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.56 EPS. As a group, research analysts anticipate that Masimo will post 2.92 earnings per share for the current year.

In other Masimo news, insider Ramshorst David J. Van sold 1,325 shares of the business’s stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $125.00, for a total value of $165,625.00. Following the completion of the transaction, the insider now owns 2,325 shares of the company’s stock, valued at approximately $290,625. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Sanford Fitch sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $113.14, for a total transaction of $226,280.00. The disclosure for this sale can be found here. In the last three months, insiders sold 666,033 shares of company stock valued at $79,900,568. Corporate insiders own 12.60% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in MASI. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Masimo in the 2nd quarter valued at $109,000. Ibex Investors LLC purchased a new stake in shares of Masimo in the 3rd quarter valued at $208,000. CIBC Asset Management Inc purchased a new stake in shares of Masimo in the 3rd quarter valued at $227,000. Parametrica Management Ltd purchased a new stake in shares of Masimo in the 3rd quarter valued at $234,000. Finally, US Bancorp DE boosted its stake in shares of Masimo by 36.9% in the 2nd quarter. US Bancorp DE now owns 1,980 shares of the medical equipment provider’s stock valued at $193,000 after purchasing an additional 534 shares in the last quarter. 83.29% of the stock is owned by institutional investors and hedge funds.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Further Reading: Hedge Funds – How They Work For Investors

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.